CAR T-cell therapy represents another modality for targeting mesothelin, by modifying autologous T-cells to express a mesothelin-binding T-cell receptor, such that binding of these cells to mesothelin activates an anti-tumor response [70]. Here, MSLN is linked to neoplasm.